cache/8100b579924f0f8db153894c2cf56fd4677df0696992f814014b96246d4be584

COM:SYNOXTHERAPEUTICS

SynOx Therapeutics

  • Privately Held
OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    SynOx Therapeutics is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies. The company's mission is to establish emactuzumab as a best-in-class drug of choice to address unmet needs and improve the quality of life for as many patients as ...Show More